Dashboard
Manage Tickers

AVIRAtea Pharmaceuticals, Inc.

Nasdaq ateapharma.com


$ 3.95 $ -0.01 (-0.25 %)    

Thursday, 06-Jun-2024 09:33:14 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 463.45 $ -0.23 (-0.05 %)
DIA $ 389.53 $ 0.82 (0.21 %)
SPY $ 534.98 $ 0.01 (0 %)
TLT $ 93.14 $ 0.26 (0.28 %)
GLD $ 218.63 $ 0.79 (0.36 %)
$ 3.96
$ 3.95
$ 3.87 x 502
$ 3.95 x 497
$ 3.95 - $ 3.95
$ 2.77 - $ 4.60
301,630
na
332.31M
$ 0.69
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
15 12-10-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

atea-pharmaceuticals-shares-promising-data-from-therapy-study-for-hepatitis-c-virus
Atea Pharmaceuticals Shares Promising Data...
06/05/2024 14:55:19

Atea Pharmaceuticals announces 97% SVR12 in Phase 2 HCV study of bemnifosbuvir. Data shows high efficacy, safety, and low resis...

atea-pharmaceuticals-presents-initail-phase-2-results-for-bemnifosbuvir-and-ruzasvir-mix-in-treating-hepatitis-c-at-the-2024-easl-congress
Atea Pharmaceuticals Presents Initail Phas...
06/05/2024 11:54:45

97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Stud...

atea-pharmaceuticals-announced-it-will-presents-new-data-showcasing-potential-best-in-class-combination-profile-of-bemnifosbuvir-and-ruzasvir-for-treatment-of-hepatitis-c-virus-at-easl-congress-2024
Atea Pharmaceuticals Announced It Will Pre...
05/22/2024 11:06:51

atea-pharmaceuticals-q1-2024-gaap-eps-075-misses-061-estimate
Atea Pharmaceuticals Q1 2024 GAAP EPS $(0....
05/14/2024 20:16:37

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate o...

atea-pharmaceuticals-completes-patient-enrollment-in-global-phase-3-sunrise-3-trial-evaluating-bemnifosbuvir-for-covid-19-in-high-risk-patients
Atea Pharmaceuticals Completes Patient Enr...
03/27/2024 11:05:03

recap-atea-pharmaceuticals-q4-earnings
Recap: Atea Pharmaceuticals Q4 Earnings
02/28/2024 21:35:31

atea-pharmaceuticals-q4-2023-gaap-eps-047-beats-051-estimate
Atea Pharmaceuticals Q4 2023 GAAP EPS $(0....
02/28/2024 21:31:46

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of ...

earnings-scheduled-for-february-28-2024
Earnings Scheduled For February 28, 2024
02/28/2024 11:24:02

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

atea-pharmaceuticals-earnings-preview
Atea Pharmaceuticals Earnings Preview
02/27/2024 20:01:59

atea-pharmaceuticals-hepatitis-c-virus-candidate-shows-efficacy
Atea Pharmaceuticals' Hepatitis C Virus Ca...
01/09/2024 18:33:35

Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 c...

atea-pharmaceuticals-announces-initial-data-from-phase-2-study-for-hepatitis-c-virus-and-significant-enrollment-milestone-for-phase-3-sunrise-3-trial-for-covid-19
Atea Pharmaceuticals Announces Initial Dat...
01/08/2024 21:09:17

A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort ...

atea-pharmaceuticals-inc-receives-orphan-designation-status-from-us-fda-for-a-phosphoramidate-oral-prodrug-of-a-unique-6-modified-purine-nucleotide-for-treatment-of-disease-caused-by-dengue-virus
Atea Pharmaceuticals Inc. Receives Orphan ...
12/18/2023 14:49:33

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=976523  

atea-pharmaceuticals-q3-eps-040-beats-048-estimate
Atea Pharmaceuticals Q3 EPS $(0.40) Beats ...
11/08/2023 22:19:01

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of ...

earnings-scheduled-for-november-8-2023
Earnings Scheduled For November 8, 2023
11/08/2023 09:21:00

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.

atea-pharmaceuticalss-earnings-outlook
Atea Pharmaceuticals's Earnings Outlook
11/07/2023 18:01:52

stocks-that-hit-52-week-lows-on-monday
Stocks That Hit 52-Week Lows On Monday
10/02/2023 17:00:10

  On Monday, 369 companies set new 52-week lows.

benzingas-top-ratings-upgrades-downgrades-for-august-10-2023
Benzinga's Top Ratings Upgrades, Downgrade...
08/10/2023 15:00:36

jp-morgan-downgrades-atea-pharmaceuticals-to-underweight
JP Morgan Downgrades Atea Pharmaceuticals ...
08/10/2023 09:28:54

JP Morgan analyst Eric Joseph downgrades Atea Pharmaceuticals (NASDAQ:AVIR) from Neutral to Underweight.

atea-pharmaceuticals-q2-eps-034-beats-047-estimate
Atea Pharmaceuticals Q2 EPS $(0.34) Beats ...
08/08/2023 21:39:38

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of ...

earnings-scheduled-for-august-8-2023
Earnings Scheduled For August 8, 2023
08/08/2023 08:48:24

Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly earnings at $0.21 per share o...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION